Comparison of quality of life among patients treated with a biologic drug who suffer from hidradenitis suppurativa or suffer from a severe form of psoriasis

Cilj istraživanja: Cilj ovog istraživanja bio je usporediti kvalitetu života u pacijenata na terapiji biološkim lijekom koji boluju od hidradenitis suppurativa ili boluju od teškog oblika psorijaze Ispitanici i metode: U opažajnu, retrospektivnu studiju parova uključeno je ukupno 52 pacijenta na terapiji biološkim lijekom, 26 s dijagnozom hidradenitis suppurativa i 26 s dijagnozom teškog oblika psorijaze. Korištena je anketa i upitnici: Dermatološki indeks kvalitete života (DLQI), Beckov inventar depresije za žene i muškarce (BDI-II) i Upitnik o radnoj učinkovitosti i smetnjama u radu V2.0 (WPAI:GH). Uspoređen je rezultat DLQI između HS i psorijaze te između žena i muškaraca unutar skupina. Skupine su uspoređene s obzirom na broj promjenama zahvaćenih područja, dobi pri pojavi simptoma i postavljanju dijagnoze, prisutnost komorbiditeta, zadovoljstvo biološkom terapijom, kvalitetu života, prisutnost depresije, smetnje u radu i obavljanju svakodnevnih aktivnosti. Rezultati: Rezultat DLQI u pacijenata s dijagnozom hidradenitis suppurativa (7,4 ± 5,8) značajno je lošiji u odnosu na pacijente s dijagnozom teškog oblika psorijaze (1,8 ± 2,5); P
Objectives: The aim of the present study was to compare quality of life among patients treated with a biologic drug who suffer from hidradenitis suppurativa or suffer from a severe form of psoriasis. Subjects and methods: A total of 52 patients treated with biological drug, 26 with diagnosis of hidradenitis suppurativa and 26 with diagnosis of a severe form of psoriasis were included in the observational, retrospective study of couples. A survey and questionnaires: Dermatology Quality of Life Index (DLQI), Beck's Depression Inventory for women and men (BDI-II) and Work Productivity and Acitivity Impairment Questionnaire V2.0 (WPAI:GH) were used. DLQI results were compared between HS and psoriasis and between women and men within the groups. The groups were compared with regard to the number of affected skin areas, age at onset of symptoms and official diagnosis, presence of comorbidities, satisfaction with biological therapy, quality of life, presence of depression, interference with work and performing daily activities. Results: The DLQI score among patients with hidradenitis suppurativa (7.4 ± 5.8) was significantly worse than DLQI score in the psoriasis group (1.8 ± 2.5); P